upon entry to the hospital, baseline measurements are taken. this includes checking vital signs such as heart rate, systolic and diastolic blood pressure, and recording breathing patterns.

blood samples are drawn to evaluate haematology, blood chemistry, creatinine level, and urinalysis. these results provide a reference for later comparison.

an intravenous line is placed to allow delivery of the study medication.

the infusion equipment is prepared according to the protocol for cangrelor administration.

the study drug kengrexal 50 mg powder for concentrate for solution for injection/infusion is reconstituted and given by intravenous route.

the dose is 00 µg/kg (microgram per kilogram of body weight). the exact amount is calculated based on the patient’s weight.

the infusion is started at the beginning of the percutaneous vascular procedure and continues for the duration of the procedure.

continuous observation of heart rate, blood pressure, and respiratory status is performed while the infusion is running.

urine output is measured to detect any decrease that might be related to the medication.

after the infusion stops, the patient is observed for at least 72 hours.

the monitoring focuses on signs of bleeding (major, clinically relevant non‑major, or minor), need for blood product transfusion, new or worsening breathing difficulties such as dyspnoea, wheezing, or respiratory distress, and changes in kidney function indicated by creatinine levels.

vital signs continue to be recorded regularly.

repeat blood and urine tests are performed to compare with the baseline values, checking for any changes in haematology, chemistry, and creatinine.

the results help assess the safety profile of the medication.

once the observation period is completed and no safety concerns are identified, discharge instructions are provided.

the patient receives information on signs to watch for after leaving the hospital, such as unexpected bleeding or breathing problems.